Search results for "Antifungal prophylaxis"

showing 4 items of 4 documents

Invasive candida infections in neonates after major surgery: Current evidence and new directions

2021

Infections represent a serious health problem in neonates. Invasive Candida infections (ICIs) are still a leading cause of mortality and morbidity in neonatal intensive care units (NICUs). Infants hospitalized in NICUs are at high risk of ICIs, because of several risk factors: broad spectrum antibiotic treatments, central catheters and other invasive devices, fungal colonization, and impaired immune responses. In this review we summarize 19 published studies which provide the prevalence of previous surgery in neonates with invasive Candida infections. We also provide an overview of risk factors for ICIs after major surgery, fungal colonization, and innate defense mechanisms against fungi, a…

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtymedicine.drug_classInvasive Candida infections030106 microbiologylcsh:MedicineInvasive Candida infectionCandida infections03 medical and health sciencesBroad spectrumNeonatal surgeryinvasive <i>Candida</i> infections0302 clinical medicineInvasive fungal infectionInvasive fungal infectionsIntensive careEpidemiologyFungal colonizationImmunology and AllergyMedicineAntifungal prophylaxi030212 general & internal medicineMolecular BiologyNewbornsGeneral Immunology and Microbiologybusiness.industrylcsh:RImpaired immune responsesNewbornSurgeryNeonatal surgeryInfectious DiseasesSettore MED/20SurgeryAntifungal prophylaxisAntifungal prophylaxis; Invasive Candida infections; Invasive fungal infections; Neonatal surgery; Newborns; Surgerybusiness
researchProduct

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

2009

Patients surviving invasive fungal disease (IFD) and needing further antineoplastic chemotherapy are at high risk of recurrent fungal infection. In the absence of randomised controlled trials in this area, secondary prophylactic regimens are diverse. From 448 patients registered with the Multinational Case Registry of Secondary Antifungal Prophylaxis, we performed an analysis of patients receiving caspofungin (CAS) or itraconazole (ITC). All patients had an underlying haematological malignancy and had been diagnosed with an episode of IFD earlier in their course of treatment. Data collected comprised demographics, underlying disease, first episode of IFD, antifungal prophylaxis, incidence a…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleAspergillosisChemopreventionEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundCaspofunginInternal medicinemedicineHumansAspergillosisPharmacology (medical)RegistriesMycosisAgedFirst episodebusiness.industryIncidence (epidemiology)Stem cell transplantationGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTransplantationTreatment OutcomeInfectious DiseasesMycoseschemistryHematologic NeoplasmsChemoprophylaxisFemaleAntifungal prophylaxisItraconazoleCaspofunginbusinessmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

2017

This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox re…

Lung DiseasesMaleOncologylung diseaseAntifungal AgentsSkin Neoplasmsmedicine.medical_treatment030230 surgeryTHERAPY030207 dermatology & venereal diseases0302 clinical medicinelung transplantation/pulmonologypatient safetyEPIDEMIOLOGYMedicineImmunology and AllergyPharmacology (medical)malignant [complication]RISKHazard ratioImmunosuppressionMiddle AgedPrognosisinfection and infectious agents - fungalPRACTICE GUIDELINEScomplication: malignantCarcinoma Squamous Cellantifungal [antibiotic]FemaleLung Transplantationmedicine.drugCohort studyAdultmedicine.medical_specialtyAdolescentinfectious diseaseSOCIETYANTIFUNGAL PROPHYLAXISclinical research/practiceArticleYoung Adult03 medical and health sciencesantibiotic: antifungal; clinical research/practice; complication: malignant; health services and outcomes research; infection and infectious agents - fungal; infectious disease; lung disease; lung transplantation/pulmonology; patient safety; Immunology and Allergy; Transplantation; Pharmacology (medical)LONG-TERM VORICONAZOLEInternal medicineHumansLung transplantationEXPOSUREAgedRetrospective StudiesVoriconazoleTransplantationSKIN-CANCERbusiness.industryProportional hazards modelRetrospective cohort studyantibiotic: antifungalhealth services and outcomes researchTransplant RecipientsSurgeryTransplantationRECIPIENTSVoriconazolebusinessFollow-Up Studies
researchProduct

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct